Cargando…

Hemorrhoid management in women: the role of tribenoside + lidocaine

Hemorrhoids are commonly reported in women. However, despite the high prevalence of hemorrhoids in women and the major impact of this condition on quality of life, specific evidence and recommendations on the treatment of hemorrhoids in women are scant. This paper reviews various options in current...

Descripción completa

Detalles Bibliográficos
Autor principal: Kestřánek, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752749/
https://www.ncbi.nlm.nih.gov/pubmed/31555338
http://dx.doi.org/10.7573/dic.212602
_version_ 1783452776822472704
author Kestřánek, Jan
author_facet Kestřánek, Jan
author_sort Kestřánek, Jan
collection PubMed
description Hemorrhoids are commonly reported in women. However, despite the high prevalence of hemorrhoids in women and the major impact of this condition on quality of life, specific evidence and recommendations on the treatment of hemorrhoids in women are scant. This paper reviews various options in current therapy for hemorrhoids in women—namely, medical intervention (topical and systemic drug therapy)—and discusses the available clinical evidence for an appropriate use of over-the-counter topical formulations for the symptomatic treatment of hemorrhoids. Its focus is on a medical preparation containing tribenoside + lidocaine, available as a rectal cream (tribenoside 5%/lidocaine 2%) and a suppository (tribenoside 400 mg/lidocaine 40 mg) and marketed under the brand Procto-Glyvenol(®) (Recordati, SpA, Italy). Given its rapid comprehensive efficacy on all the different symptoms of hemorrhoids, the tribenoside + lidocaine combination can find a place in the treatment of this hemorrhoidal disease. Importantly, its efficacy and tolerability have been formally evaluated in several well-conducted studies, some of which were specifically conducted in women. In particular, tribenoside + lidocaine can be safely administered in postpartum women and in pregnant women after the first trimester of pregnancy. In pregnant women, the tribenoside/lidocaine combination significantly improved both subjective and objective symptoms of hemorrhoids. Fast onset of symptom relief was reported from 10 minutes after administration, lasting up to 10–12 hours. On these bases, tribenoside + lidocaine can represent a fast, effective, and safe option to treat hemorrhoids when conservative therapy is indicated, and it deserves consideration as a first-line treatment of this disease in clinical practice.
format Online
Article
Text
id pubmed-6752749
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-67527492019-09-25 Hemorrhoid management in women: the role of tribenoside + lidocaine Kestřánek, Jan Drugs Context Review Hemorrhoids are commonly reported in women. However, despite the high prevalence of hemorrhoids in women and the major impact of this condition on quality of life, specific evidence and recommendations on the treatment of hemorrhoids in women are scant. This paper reviews various options in current therapy for hemorrhoids in women—namely, medical intervention (topical and systemic drug therapy)—and discusses the available clinical evidence for an appropriate use of over-the-counter topical formulations for the symptomatic treatment of hemorrhoids. Its focus is on a medical preparation containing tribenoside + lidocaine, available as a rectal cream (tribenoside 5%/lidocaine 2%) and a suppository (tribenoside 400 mg/lidocaine 40 mg) and marketed under the brand Procto-Glyvenol(®) (Recordati, SpA, Italy). Given its rapid comprehensive efficacy on all the different symptoms of hemorrhoids, the tribenoside + lidocaine combination can find a place in the treatment of this hemorrhoidal disease. Importantly, its efficacy and tolerability have been formally evaluated in several well-conducted studies, some of which were specifically conducted in women. In particular, tribenoside + lidocaine can be safely administered in postpartum women and in pregnant women after the first trimester of pregnancy. In pregnant women, the tribenoside/lidocaine combination significantly improved both subjective and objective symptoms of hemorrhoids. Fast onset of symptom relief was reported from 10 minutes after administration, lasting up to 10–12 hours. On these bases, tribenoside + lidocaine can represent a fast, effective, and safe option to treat hemorrhoids when conservative therapy is indicated, and it deserves consideration as a first-line treatment of this disease in clinical practice. BioExcel Publishing Ltd 2019-09-13 /pmc/articles/PMC6752749/ /pubmed/31555338 http://dx.doi.org/10.7573/dic.212602 Text en Copyright © 2019 Kestřánek J. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Review
Kestřánek, Jan
Hemorrhoid management in women: the role of tribenoside + lidocaine
title Hemorrhoid management in women: the role of tribenoside + lidocaine
title_full Hemorrhoid management in women: the role of tribenoside + lidocaine
title_fullStr Hemorrhoid management in women: the role of tribenoside + lidocaine
title_full_unstemmed Hemorrhoid management in women: the role of tribenoside + lidocaine
title_short Hemorrhoid management in women: the role of tribenoside + lidocaine
title_sort hemorrhoid management in women: the role of tribenoside + lidocaine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752749/
https://www.ncbi.nlm.nih.gov/pubmed/31555338
http://dx.doi.org/10.7573/dic.212602
work_keys_str_mv AT kestranekjan hemorrhoidmanagementinwomentheroleoftribenosidelidocaine